Treatment alert for Sjogrens TWINSS study: Iscalimab CD40/CD40L monoclonal Ab: Improves disease activity Also helps fati
Tweet Content
Treatment alert for Sjogrens
TWINSS study:
Iscalimab CD40/CD40L monoclonal Ab:
Improves disease activity
Also helps fatigue and sicca, not pain
Dazodalibep - CD40L antagonist also reduce symptoms/disease activity
Year in Review #ACR24 Pillinger
@RheumNow https://t.co/WjHuEpm9XW
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off